Zydus Lifesciences and Torrent Pharma to Co-Market Semaglutide Injection in India
Ahmedabad, March 18, 2026 – Zydus Lifesciences Limited and Torrent Pharmaceuticals Limited have entered into a licensing and supply agreement to co-market Semaglutide Injection in the Indian market.Under the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has secured semi-exclusive rights to co-market the product in India under its brand name SEMBOLIC TM. Zydus will market the product under its brands SEMAGLYN TM, MASHEMA TM, and ALTERME TM. Torrent Pharma will pay an upfront licensing fee to Zydus.
Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable patient-friendly pen device. The formulation, combined with the reusable pen device, is designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance.
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, and for chronic weight management in adults with obesity or overweight with weight-related comorbidities.
This partnership combines Zydus's product development and manufacturing capabilities with Torrent Pharma's market expertise in chronic therapies and extensive field force across India, aiming to expand access to advanced GLP-1 therapies for metabolic disorders.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited is an innovation-led global life sciences company with a presence across pharmaceuticals and consumer wellness. The Group employs more than 29,000 people worldwide, including 1,500 scientists engaged in research and development.
About Torrent Pharmaceuticals Limited
Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is a specialty-focused global pharmaceutical company. It operates in more than 50 countries and has 8 manufacturing facilities, 5 of which are USFDA approved.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Last edited by a moderator: